Annovis Bio (NYSE: ANVS) has promoted Cheng Fang, Ph.D., to chief scientific officer, the company announced. Fang, who joined Annovis in 2021 and most recently served as senior vice president of research and development, will oversee scientific strategy and research operations across the company’s Alzheimer’s disease and Parkinson’s disease programs. His responsibilities include translational science, clinical development, biomarker strategy and regulatory interactions.
The promotion comes at a critical juncture for Annovis as it advances its lead drug candidate, buntanetap, toward top-line data from its pivotal Phase 3 Alzheimer’s disease study and a subsequent New Drug Application submission. Fang has played a key role in advancing the company’s clinical development efforts and will lead its scientific strategy through upcoming clinical and regulatory milestones, according to the company.
Annovis Bio is a Phase 3 clinical-stage biotechnology company headquartered in Malvern, Pennsylvania, focused on developing treatments for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD). The company’s lead drug candidate, buntanetap (formerly posiphen), is an investigational once-daily oral therapy that inhibits the translation of multiple neurotoxic proteins, including APP and amyloid beta, tau, alpha-synuclein, and TDP-43, through a specific RNA-targeting mechanism of action. By addressing the underlying causes of neurodegeneration, Annovis aims to halt disease progression and improve cognitive and motor functions in patients.
The appointment of Fang signals Annovis’s commitment to advancing its pipeline as it approaches a pivotal data readout. The Phase 3 Alzheimer’s study is a key step toward potential regulatory approval, and a positive outcome could represent a significant advancement in the treatment of Alzheimer’s disease, a condition affecting millions worldwide. The company’s approach targets multiple toxic proteins implicated in neurodegeneration, which may offer a broader therapeutic effect compared to single-target therapies.
For more information about Annovis Bio, visit www.annovisbio.com and follow on LinkedIn, YouTube, and X. The full press release is available at https://ibn.fm/c9jdt.
